Amylyx Pharmaceuticals, Inc. (AMLX)

Every figure this model derived for AMLX, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 138,000 PaymentsToAcquirePropertyPlantAndEquipment 2025-12-31
cash 250,760,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 256,338,000 AssetsCurrent 2026-06-30
current liabilities 21,150,000 LiabilitiesCurrent 2026-06-30
equity 239,167,000 StockholdersEquity 2026-06-30
ocf -126,577,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 0 RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31
sbc 27,900,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up AMLX on one particular measure came for.

RatioValue
current ratio12.12
current ratio reported12.12
dilution pct38.81
growth cv1.4
revenue growth-100.0
revenue growth per share-100.0

What to be careful about

What this model itself distrusts about AMLX's figures. Written by the derivation as it ran, not added afterwards.